{"disease":{"id":"grade-i-neuroendocrine-carcinoma","name":"grade i neuroendocrine carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04464122","title":"Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT03728361","title":"Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Dwight Owen","has_results":false},{"nct_id":"NCT03136055","title":"Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"University of California, San Francisco","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}